NDAORAL-28TABLET
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LO/OVRAL-28 is an oral contraceptive combining ethinyl estradiol and norgestrel in a 28-day tablet pack. It prevents pregnancy through hormonal suppression of ovulation and cervical mucus thickening. This product represents a legacy combined oral contraceptive (COC) formulation with low-dose estrogen.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), brand team size is likely lean, focused on defensive positioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LO/OVRAL-28 offers limited growth trajectory and skill development opportunity within a legacy, commoditized product line. Career advancement is constrained by stagnant market dynamics, minimal innovation, and pressure to defend share against generics.
Brand ManagerRegulatory Affairs Specialist
Worked on LO/OVRAL-28 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.